American International Group, Inc. Caribou Biosciences, Inc. Transaction History

American International Group, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$4.82 - $8.26 $1,667 - $2,857	-346 Reduced 0.85%	40,347 $207,000
Q4 2023 Feb 13, 2024	BUY	$3.58 - $6.25 $12,218 - $21,331	3,413 Added 9.16%	40,693 $233,000
Q3 2023 Nov 13, 2023	BUY	$4.08 - $8.14 $40,392 - $80,586	9,900 Added 36.16%	37,280 $178,000
Q2 2023 Aug 04, 2023	BUY	$4.04 - $5.47 $1,248 - $1,690	309 Added 1.14%	27,380 $116,000
Q1 2023 May 12, 2023	BUY	$4.3 - $7.78 $2,322 - $4,201	540 Added 2.04%	27,071 $143,000
Q4 2022 Feb 10, 2023	SELL	$5.57 - $11.01 $540 - $1,067	-97 Reduced 0.36%	26,531 $166,000
Q3 2022 Nov 14, 2022	BUY	$5.34 - $12.79 $7,230 - $17,317	1,354 Added 5.36%	26,628 $281,000
Q2 2022 Aug 12, 2022	BUY	$5.1 - $9.74 $107 - $204	21 Added 0.08%	25,274 $137,000
Q1 2022 May 13, 2022	BUY	$8.42 - $15.32 $121,896 - $221,787	14,477 Added 134.34%	25,253 $232,000
Q4 2021 Feb 11, 2022	BUY	$14.59 - $23.26 $4,085 - $6,512	280 Added 2.67%	10,776 $163,000
Q3 2021 Nov 12, 2021	BUY	$15.75 - $30.29 $165,312 - $317,923	10,496 New	10,496 $251,000

145

53.7M

32.5K

89.8K

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $119M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.